CONTEXT: This paper published in the AJMC describes the findings from a retrospective chart review of migraine sufferers taking Erenumab | Data from 5 US headache centres only (n = 1034) | As concluded by the authors, “Further long-term research across various clinical practice settings is needed to better understand real-world patient outcomes and treatment patterns with erenumab therapy,”
IMPACT: Low
READ TIME: 3 mins
Quality Level Mean [1 – 10]: 6
1. “However, 22% of these patients “were prescribed treatments during the study period other than erenumab that may be potentially associated with constipation,” the authors said.”
2. “To address this knowledge gap, researchers “aimed to characterize the real-world treatment profiles, clinical outcomes, and healthcare resource utilization of patients prescribed erenumab from select major US headache centers.””
3. “At the end of the study period, 790 (76%) patients continued with erenumab while 244 stopped treatment.”
4. ““Further long-term research across various clinical practice settings is needed to better understand real-world patient outcomes and treatment patterns with erenumab therapy,” the authors concluded.”
5. “Real-world treatment profiles, clinical outcomes, and healthcare resource utilization of patients with migraine prescribed erenumab: a multicenter chart-review study of US headache centers.”
Source URL: https://www.ajmc.com/view/real-world-data-detail-erenumab-s-efficacy-in-chronic-migraineurs